Natural plant functional component based on cell function regulation, natural plant composition and application of natural plant functional component and natural plant composition

Abstract

The invention relates to a natural plant functional component based on cell function regulation, a natural plant composition and application thereof. The natural plant composition is prepared from the following raw material components in parts by weight: 1000 to 1600 parts of phospholipid, 200 to 400 parts of cholesterol, 200 to 400 parts of prinsepia utilis royle oil, 100 to 300 parts of ergothioneine and 200 to 500 parts of nicotinamide mononucleotide. Compared with the prior art, the composition not only can cover multi-target composite components with ROS removal, mitochondrial autophagy activation and NAD + level improvement, but also can improve the component permeability by optimizing the delivery technology, thereby effectively improving the skin anti-aging effect and the like.

Description

TECHNICAL FIELD

[0001] The present application belongs to the technical field of daily chemicals, and relates to a natural plant efficacy component based on cell function regulation. The natural plant composition and application thereof. BACKGROUND

[0002] Skin aging is the result of the combined action of endogenous (ageing) and exogenous (ultraviolet light, pollution) factors, and its essence is the macroscopic manifestation of cell function decline. Recent studies have shown that mitochondrial dysfunction is the core inducer of skin aging: as the "energy factory" and "oxidative stress regulation center" of cells, mitochondria bear three core biological functions: through the tricarboxylic acid cycle (TCA) and oxidative phosphorylation (OXPHOS), they provide energy for cell proliferation and repair; as the main site of reactive oxygen species (ROS), they maintain the redox balance through antioxidant systems such as thioredoxin-TrxR; and they regulate cell survival through the release of mitochondrial membrane potential and cytochrome C, etc. When mitochondria function declines, the above functions are simultaneously impaired, ultimately resulting in decreased skin cell proliferation (weakened barrier function), accumulated oxidative damage (pigmentation, wrinkles), and accelerated cell apoptosis (loose skin), so targeting the regulation of mitochondrial function is a key breakthrough for improving skin aging.

[0003] Mitochondrial function decline is not caused by a single factor, but is the result of multiple mechanisms acting in concert: first, abnormal mitochondrial electron transport chain (ETC) can cause excessive production of ROS such as superoxide anion (O2 - ), hydrogen peroxide (H2O2), which exceeds the clearance capacity of the antioxidant system, and further oxidatively damages mitochondrial membrane lipids (destroys membrane potential), mitochondrial DNA (mtDNA, causes abnormal function of respiratory chain complexes), and matrix proteins (such as inactivated metabolic enzymes), forming a vicious cycle of "oxidative damage-function decline"; second, mitochondrial autophagy, as a key mechanism for removing damaged mitochondria, relies on the PINK1 / Parkin pathway to recognize and label abnormal mitochondria, and degrades them through autophagolysosomes, but under conditions of aging or pathology, the activity of this pathway decreases (such as decreased expression of PINK1), leading to failure to remove damaged mitochondria in a timely manner, further exacerbating ROS leakage and mtDNA mutation; third, NAD+, as a key coenzyme for mitochondrial energy metabolism (such as TCA cycle) and DNA repair (such as PARP enzyme), its level decreases significantly with age (due to decreased activity of the rate-limiting enzyme NAMPT and increased activity of the consumption enzyme CD38), directly inhibiting the function of deacetylases such as SIRT1 (which regulates mitochondrial biogenesis and autophagy), and accelerating mitochondrial function decline.

[0004] For example, CN118717590A provides a composition containing prunus armeniaca oil, a preparation method and application thereof. The composition includes the following raw materials in parts by weight: prunus armeniaca oil, ceramide E, triple collagen, citrus extract, bisabolol, panthenol, etc. This patent can only improve skin repair and anti-aging effect to a certain extent, but it is more aimed at improving the apparent aging of the skin surface, and the regulation effect of targeting mitochondria function is not good, resulting in unsatisfactory skin anti-aging effect. SUMMARY

[0005] The purpose of the present application is to provide a natural plant efficacy component based on cell function regulation, a natural plant composition and its application, to realize multi-target complex components that can cover ROS removal, mitochondrial autophagy activation and NAD+ level improvement, and to improve the penetration rate of components through optimized delivery technology, thereby effectively improving the skin anti-aging effect, etc.

[0006] The reason for presenting the present application is that the present application has found that the existing skin anti-aging technology mainly has two limitations: (1) On the one hand, existing products mainly use single active ingredients to intervene mitochondrial function, such as antioxidants such as vitamin E and coenzyme Q10, which can only relieve oxidative stress by removing ROS, but cannot repair damaged mitochondrial DNA (mtDNA) or activate mitochondrial autophagy; autophagy activators such as rapamycin analogues can promote mitochondrial autophagy, but are immunosuppressants, and long-term use may cause skin immunosuppression; NAD+ precursors such as nicotinamide riboside (NR) can increase NAD+ levels, but have low bioavailability and need to be used in high doses, and single NAD+ cannot solve the problem of ROS accumulation; such "single target regulation" cannot cover the multiple mechanisms of mitochondrial function decline, resulting in limited overall anti-aging effect. (2) On the other hand, although natural plant extracts are widely concerned due to their high safety, their molecular characteristics result in poor stability of mixed preparations; at the same time, most natural ingredients are difficult to penetrate cell membranes and enter mitochondria due to their large molecular weight or strong polarity.

[0007] The purpose of the present application can be achieved by the following technical solutions: In a first aspect, the present application provides a natural plant efficacy component based on cell function regulation, which includes the following raw material components in parts by weight: prunus armeniaca oil 200-400 parts, ergothioneine 100-300 parts, nicotinamide mononucleotide 200-500 parts. At this time, the natural plant efficacy component can be directly added to the skin care product base auxiliary material after simple mixing.

[0008] In the second aspect, the present application provides a natural plant composition based on cell function regulation, comprising the following raw material components in parts by weight: phospholipid 1000-1600 parts, cholesterol 200-400 parts, Prinsepia uniflora oil 200-400 parts, ergothioneine 100-300 parts, nicotinamide mononucleotide 200-500 parts. At this time, by adding phospholipid and cholesterol and other components, the natural plant composition forms a liposome functional component and is used in a skin care product base auxiliary material. In the third aspect, the present application provides a preparation method of a natural plant composition based on cell function regulation, comprising the following steps: S1, phospholipid, cholesterol, and Prinsepia uniflora oil are weighed and dissolved in a solvent, stirred until completely dissolved, then transferred to an evaporation container, and the solvent is removed. At this time, a uniform composite phospholipid film will form on the bottom surface of the evaporation container; S2, the phosphoric acid buffer solution, ergothioneine, and nicotinamide mononucleotide are stirred and mixed uniformly to obtain an aqueous phase mixed solution; S3, the aqueous phase mixed solution obtained in S2 is added to the evaporation container in S1, the composite phospholipid film is hydrated, and then ultrasonic treatment is performed to obtain Prinsepia uniflora oil-ergothioneine-NMN composite functional liposomes, which are the natural plant composition.

[0009] Further, in S1, the mass ratio of cholesterol to phospholipid is (1-2):(5-8), and the mass ratio of Prinsepia uniflora oil to phospholipid is (1-2):(5-8). In addition, the ratio of the amount of phospholipid added to the solvent can be (1-3) g:(10-30) mL.

[0010] Further, in S1, the solvent used can be ethanol.

[0011] Further, in S2, the ratio of the amount of phosphoric acid buffer solution, ergothioneine, and nicotinamide mononucleotide added is (20-40) mL:(100-300) mg:(200-500) mg.

[0012] Further, in S2, the pH of the phosphoric acid buffer solution is 6.5-7.0, and the concentration can be 0.08-0.12 mol / L, for example, 0.1 mol / L.

[0013] Further, in S3, the amount of aqueous phase mixed solution and composite phospholipid film added satisfies the mass ratio of ergothioneine to nicotinamide mononucleotide (200-400):(100-300):(200-500).

[0014] Further, in S3, the hydration temperature is 45-55°C, and the time is 15-30 minutes; The ultrasonic treatment time is 3-5 minutes, and the ultrasonic power is 200-400 W.

[0015] In a fourth aspect, the present application provides a use of the natural plant composition based on cell function regulation in the preparation of an anti-aging skin care product.

[0016] Further, the anti-aging skin care product is a cream, a skin care water, an essence or a lotion.

[0017] In a fifth aspect, the present application provides an anti-aging skin care product, comprising a base auxiliary material and an efficacy component, wherein the efficacy component is the natural plant composition based on cell function regulation as described in the first aspect, and the addition amount of the efficacy component is 5-10 wt%.

[0018] Further, the skin care product is a cream, and the base auxiliary material comprises an A-phase auxiliary material, a B-phase auxiliary material, a C-phase auxiliary material and a D-phase auxiliary material, wherein, based on the total weight of the skin care product, the A-phase auxiliary material comprises glycerin 5-10%, propylene glycol 3-10%, trehalose 0.5-2%, sodium hyaluronate 0.01-1%, nicotinamide 0.5-5%, panthenol 0.1-5%, acrylates / C10-30 alkyl acrylate crosspolymer 0.1-2%, PEG-100 stearate 0.1-2%, disodium EDTA 0.01-1%; the B-phase auxiliary material comprises isopropyl isostearate 0.1-5%, caprylic / capric triglyceride 0.1-5%, glyceryl stearate 0.1-5%, dimethicone 0.1-4%, squalane 0.1-5%, cetyl stearyl alcohol 0.1-5%, behenyl alcohol 0.1-2%, polysorbate-80 0.1-2%; the C-phase auxiliary material comprises arginine 0.1-2%; the D-phase auxiliary material comprises fragrance 0.1-2%, phenoxyethanol 0.01-1%.

[0019] Compared with the prior art, the present application has the following advantages: (1) Multi-target synergistic regulation of mitochondrial function, breaking the limitation of single-target intervention The existing anti-aging technology mainly uses a single active ingredient to intervene in the function of mitochondria, only targeting a single link of ROS scavenging, autophagy activation or NAD⁺ supplementation, resulting in limited anti-aging effect. The present application realizes the synergistic regulation of multiple mechanisms of mitochondrial function decline through the scientific proportioning of three components: Prunus armeniaca oil, ergothioneine and nicotinamide mononucleotide (NMN): Prunus armeniaca oil neutralizes ROS through vitamin E, activates the Nrf2 / ARE pathway through polyphenols to enhance the antioxidant capacity of cells, and at the same time repairs the skin barrier; Ergothioneine specifically scavenges ROS in mitochondria, upregulates the PINK1 / Parkin pathway to promote autophagy of damaged mitochondria, and maintains lysosomal degradation efficiency; NMN as a direct precursor of NAD⁺, efficiently improves intracellular NAD⁺ levels, activates SIRT1 / SIRT3, etc. "longevity proteins", promotes mitochondrial biogenesis and inhibits apoptosis.

[0020] The three synergistically act from the three dimensions of "antioxidation-autophagy clearance-energy metabolism", covering the core mechanism of mitochondrial function decline, and are significantly better than single or double component combination.

[0021] (II) Liposome encapsulation technology solves the problem of penetration and stability of natural ingredients Natural plant extracts have poor penetration and low stability of mixed preparations due to their large molecular weight and strong polarity. The technology realizes efficient loading and delivery through a liposome delivery system: Phospholipid-cholesterol membrane material is used to construct liposomes, and oil-soluble Prunus mira oil is loaded in the lipid phase, and water-soluble ergothioneine and NMN are loaded in the aqueous phase, forming a "lipid phase-aqueous phase" dual drug loading structure. The liposome carrier effectively protects the ingredients from oxidation, hydrolysis and other environmental factors, solving the problem of poor stability of natural ingredient mixed preparations. BRIEF DESCRIPTION OF DRAWINGS

[0022] Figure 1 The eye skin texture map before and after using the cream, wherein (a) is before use, (b) is two weeks after use, and (c) is four weeks after use. DETAILED DESCRIPTION

[0023] The present application will be described in detail below in conjunction with the drawings and specific examples. The present embodiment is implemented on the premise of the technical solution of the present application, and gives a detailed implementation and specific operation process, but the protection scope of the present application is not limited to the following examples.

[0024] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs. The terminology used in the specification of the present application herein is only for the purpose of describing specific embodiments and is not intended to limit the present application.

[0025] The selection scope of the terms "and / or", "or / and", "and / or" used in the present application includes any one of two or more relevant listed items, and also includes any and all combinations of the relevant listed items, including any two relevant listed items, any more relevant listed items, or all relevant listed items. It should be noted that when at least two conjunctions selected from "and / or", "or / and", "and / or" are combined to connect at least three items, it should be understood that in the present application, the technical solution undoubtedly includes the technical solution connected by "logical and", and also undoubtedly includes the technical solution connected by "logical or".

[0026] In the present application, the technical features described in an open manner include both the closed technical solution consisting of the listed features and the open technical solution containing the listed features.

[0027] In the present application, if no special description is provided, the numerical interval is considered to be continuous, and includes the minimum value and the maximum value of the range, as well as each value between the minimum value and the maximum value. Further, when the range is an integer, each integer between the minimum value and the maximum value of the range is included. In addition, when multiple ranges are provided to describe a feature or a characteristic, the ranges can be combined. In other words, unless otherwise specified, all ranges disclosed herein should be understood to include any and all sub-ranges therein.

[0028] Only some numerical ranges are specifically disclosed herein. However, any lower limit can be combined with any upper limit to form a range not explicitly recited; and any lower limit can be combined with other lower limits to form a range not explicitly recited, and likewise any upper limit can be combined with any other upper limit to form a range not explicitly recited. In addition, each individual disclosed point or single numerical value can itself be combined as a lower limit or an upper limit with any other point or single numerical value or with other lower limits or upper limits to form a range not explicitly recited.

[0029] In the present application, the temperature parameter, if not specifically limited, allows for constant temperature treatment, and also allows for treatment within a certain temperature range. The constant temperature treatment allows the temperature to fluctuate within the accuracy range controlled by the instrument. Fluctuation within a range such as ±5°C, ±4°C, ±3°C, ±2°C, ±1°C is allowed.

[0030] In the present application, "suitable" in "suitable combination", "suitable manner", "any suitable manner" and the like means that the technical solution of the present application can be implemented, the technical problems of the present application can be solved, and the expected technical effects of the present application can be achieved.

[0031] In the present application, "further", "furthermore", "in particular" and the like are used for the purpose of description, indicating differences in content, but should not be understood as limiting the scope of protection of the present application.

[0032] In the present application, "optionally", "optional" and "optional" mean optional, that is, selected from "yes" or "no" two parallel schemes. If there are multiple "optional" in a technical solution, unless otherwise specified, and there is no contradiction or mutual restriction relationship, each "optional" is independent.

[0033] In the description of the application, "multiple" means at least two, for example, two, three, etc., unless otherwise specifically limited.

[0034] Unless otherwise specified, all formulations and tests in this text occur in an environment of 25°C.

[0035] In this text, "include", "contain", "contain", "contain", "have" or other variants are intended to cover non-closed inclusion, and there is no distinction between these terms. The term "contains" means that other steps and ingredients can be added without affecting the final result. The composition and method / process of the present application comprises, consists of and consists essentially of the essential elements and limitations described herein and any additional or optional ingredients, components, steps or limitations described herein. There is no distinction between the terms "efficiency", "performance", "effect", "efficacy" in this text.

[0036] If not specifically stated, all embodiments and optional embodiments of the present application can be combined to form new technical solutions. If not specifically stated, all technical features and optional technical features of the present application can be combined to form new technical solutions.

[0037] If not specifically stated, all steps of the present application can be performed in sequence or randomly, preferably in sequence.

[0038] If not specifically stated, raw materials or processing techniques indicate that they are all conventional commercially available raw materials or conventional processing techniques in the art.

[0039] In order to effectively improve the skin anti-aging effect, the present application provides a natural plant composition based on cell function regulation, which comprises the following raw material components in parts by weight: phospholipid 1000-1600 parts, cholesterol 200-400 parts, Prunus armeniaca oil 200-400 parts, ergothioneine 100-300 parts, nicotinamide mononucleotide 200-500 parts.

[0040] The natural plant composition provided by the present application is a liposome, and by scientific matching of the Prunus armeniaca L. oil, ergothioneine and nicotinamide mononucleotide (NMN), a whole-chain regulation network of "antioxidation-autophagy clearance-energy metabolism" is constructed to block the aging process from the root: The antioxidant level: Vitamin E in the Prunus armeniaca L. oil directly neutralizes intracellular reactive oxygen species (ROS), and the polyphenolic substances contained therein activate the Nrf2 / ARE pathway to induce the expression of endogenous antioxidant enzymes such as superoxide dismutase SOD and glutathione peroxidase GPx, forming a double antioxidant barrier of "exogenous clearance + endogenous strengthening"; The autophagy clearance level: Ergothioneine is specifically enriched in the mitochondrial matrix, not only clearing ROS in the mitochondria, but also up-regulating the expression of key proteins in the PINK1 / Parkin pathway such as PINK1 kinase and Parkin ubiquitin ligase to promote the labeling and autophagosome wrapping of damaged mitochondria, while maintaining the acidic environment of lysosomes and the activity of hydrolytic enzymes to ensure efficient degradation of damaged mitochondria by autophagy lysosomes; The energy metabolism level: NMN, as a direct precursor of NAD⁺, bypasses the traditional NR-dependent NAMPT rate-limiting enzyme restriction, rapidly increases the intracellular NAD⁺ level, and activates "longevity proteins" such as SIRT1 / SIRT3-SIRT1 promotes PGC-1 alpha-mediated mitochondrial biogenesis (new mitochondria generation), and SIRT3 regulates the activity of electron transport chain complexes through deacetylation to improve ATP generation efficiency.

[0041] The synergistic effect of the three not only clears existing damaged mitochondria (autophagy), but also inhibits the generation of new damage (antioxidation), and promotes the regeneration of healthy mitochondria (energy metabolism), forming a closed-loop regulation of "clearance-inhibition-regeneration", which fundamentally reverses the skin aging problems caused by mitochondrial function decline, such as deepening of wrinkles, decrease of elasticity, and slow barrier repair.

[0042] In the preparation process, the double-drug liposome delivery system is used to achieve efficient delivery and stable loading of the components: Penetration is improved: the liposome is constructed using phospholipid-cholesterol membranes, the oil-soluble Prunus armeniaca L. oil is loaded in the lipid phase layer, and the water-soluble ergothioneine and NMN are loaded in the water phase core, forming a "lipid phase-water phase" double-drug structure; combined with low-temperature film formation, ultrasonic dispersion and other particle size control processes, the liposome can efficiently penetrate through the hydration channels of the stratum corneum (hydrophilic components) and the lipid raft structure of the cell membrane (lipophilic components); Stability is enhanced: the closed environment formed by the liposome membrane material effectively isolates the components from the external environment such as oxygen and moisture, significantly reducing the oxidation and spoilage rate of the Prunus armeniaca L. oil, and protecting the ergothioneine and NMN from hydrolytic damage, ensuring the activity retention of the components during storage and use.

[0043] The liposome-encapsulated natural plant composition provided above can be used in a skin care product, which can be any form of skin care product or cosmetic product. By way of example, it can be a skin care water, serum, emulsion, cream, freeze-dried powder, etc. Depending on the different types of skin care products, the required base ingredients are also different.

[0044] Taking a cream as an example, it comprises a base adjuvant and the liposome-encapsulated natural plant composition (or directly uses the natural plant active ingredient without liposome encapsulation) as an active ingredient, wherein the base adjuvant comprises A-phase adjuvant, B-phase adjuvant, C-phase adjuvant and D-phase adjuvant, wherein, based on the total weight of the skin care product, The A-phase adjuvant comprises glycerin 5-10%, propylene glycol 3-10%, trehalose 0.5-2%, sodium hyaluronate 0.01-1%, nicotinamide 0.5-5%, panthenol 0.1-5%, acrylates / C10-30 alkyl acrylate crosspolymer 0.1-2%, PEG-100 stearate 0.1-2%, disodium EDTA 0.01-1%, and the balance water; The B-phase adjuvant comprises isopropyl isostearate 0.1-5%, caprylic / capric triglyceride 0.1-5%, glyceryl stearate 0.1-5%, dimethicone 0.1-4%, squalane 0.1-5%, cetyl stearyl alcohol 0.1-5%, behenyl alcohol 0.1-2%, polysorbate-80 0.1-2%; The C-phase adjuvant comprises arginine 0.1-2%; The D-phase adjuvant comprises fragrance 0.1-2%, phenoxyethanol 0.01-1%; In addition, the active ingredient is added in an amount of 5-10%.

[0045] The preparation method of the above-mentioned cream comprises the following steps: a. Water phase: water is placed in a container with stirring device, and other components of A-phase are fully wet-mixed and then added to the water, which is fully stirred to completely dissolve, and heated to 75-80°C; b. Oil phase: the components of B-phase are mixed and heated to 75-80°C, and stirred to completely dissolve; c. Emulsification: the oil phase obtained in step b is added to the water phase obtained in step a, and stirred at 250-350 rpm for 3-5 min, and then homogenized at 2500-3500 rpm for 3-10 min; d. The components in C-phase are added, and stirred at 250-350 rpm for 3-5 min, and then homogenized at 2500-3500 rpm for 3-10 min, and the stirring is cooled to 40-50°C; e. The components in D-phase are added, and stirred at 250-350 rpm for 3-5 min, and then homogenized at 2500-3500 rpm for 3-10 min; f. After cooling to 35-38℃, add phase E, stir at 250-350 rpm for 3-10 minutes, then homogenize at 2500-3500 rpm for 3-10 minutes to obtain the desired face cream.

[0046] To verify the basic efficacy of the combination of sea buckthorn fruit oil, ergothioneine, and nicotinamide mononucleotide (NMN) and to evaluate the effect of liposome encapsulation technology on efficacy, a preliminary experiment was conducted. Two concentration gradients of the three components were designed, and the results were compared using key cellular indicators in both simple mixing and liposome encapsulation forms.

[0047] I. Experimental Sample Design Table 1. Preliminary Experiment: Amount and Form Design of Active Ingredients The liposome encapsulation process for experimental groups 3 and 4 (same as the preparation process in Examples 1-3 below) is as follows: S1. Weigh out phospholipids, cholesterol, and sea buckthorn oil and dissolve them fully in the solvent ethanol. Stir until completely dissolved and then transfer to an evaporation container. Evaporate at low temperature to remove the solvent. At this time, a uniform composite phospholipid film will be formed on the bottom surface of the evaporation container. S2. Mix the phosphate buffer solution, ergothioneine and nicotinamide mononucleotide to obtain an aqueous mixed solution. S3. Add the aqueous mixed solution obtained in S2 to the evaporation container in S1 to hydrate the composite phospholipid membrane at a temperature of about 50°C for about 20 minutes. Then, perform ultrasonic treatment for about 4 minutes at a power of 300W to obtain the liposome-encapsulated prickly pear oil-ergothioneine-NMN complex active ingredients.

[0048] In vitro cell experiments (1) Detection of core indicators of mitochondrial function Experimental materials: Cell: Human immortalized keratinocytes (HaCaT).

[0049] Samples: Experimental groups 1-4 in Table 1.

[0050] Reagents: JC-1 mitochondrial membrane potential detection kit, ATP detection kit (luciferase method), MitoSOX Red mitochondrial superoxide anion probe.

[0051] Experimental steps: 1. Cell seeding and sample processing HaCaT cells were seeded into 24-well plates and cultured until confluence reached 60%-70%. Then, the medium was replaced with serum-free medium containing different samples and cultured for another 24 hours.

[0052] 2. Mitochondrial membrane potential detection After incubating the MitoSOX Red probe, the fluorescence intensity was observed using a fluorescence microscope. The lower the intensity, the lower the ROS level.

[0053] 3. Measurement of ATP production After cell lysis, the supernatant was reacted with ATP detection working solution, and the chemiluminescence intensity was detected by an ELISA reader to calculate the ATP concentration.

[0054] 4. Mitochondrial ROS level detection After incubating the MitoSOX Red probe, the fluorescence intensity was observed using a fluorescence microscope. The lower the intensity, the lower the ROS level.

[0055] Table 2 Cell Experiment Values As shown in Table 2, compared with the blank control, all experimental groups containing sea buckthorn oil, ergothioneine, and NMN showed significantly increased mitochondrial membrane potential and ATP production, and significantly decreased mitochondrial ROS levels, indicating that this composition itself has a clear potential to improve mitochondrial function and combat oxidative stress. Comparing experimental groups 1 and 2, and experimental groups 3 and 4, it was found that under the same treatment, the efficacy indicators of the high-concentration groups were generally superior to those of the low-concentration groups, showing a good dose-response relationship. Furthermore, comparing experimental groups 1 and 3, and experimental groups 2 and 4, it was found that with the same dosage of active ingredients, the efficacy of the liposome-encapsulated groups was consistently superior to the simple mixture groups, indicating that the liposome delivery system used in this invention can more effectively improve the cell permeability and bioavailability of the active ingredients.

[0056] This preliminary experiment confirmed the effectiveness of the combination of sea buckthorn oil, ergothioneine, and NMN in improving mitochondrial function, and also verified that liposome encapsulation technology has a clear synergistic advantage over simple mixing. Based on these preliminary experimental results, the following examples will focus on the optimized liposome composition, and further verify and elucidate its significant anti-skin aging effects through more comprehensive in vitro cell experiments and human efficacy tests.

[0057] II. Component Proportion Design Based on the preliminary experimental results, this embodiment further optimizes and prepares a liposome-encapsulated natural plant composition. The raw material ratios of the provided active ingredients are shown in Table 3.

[0058] This embodiment takes face cream as an example, and the raw material composition of the provided functional ingredients is shown in Table 3.

[0059] Table 3. Formulations of Examples 1-3 and Comparative Examples 1-7 The preparation methods of the active ingredients in Examples 1-3 include the following steps: S1. Weigh out phospholipids, cholesterol, and sea buckthorn oil and dissolve them fully in the solvent. Stir until completely dissolved and then transfer to an evaporation container. Evaporate at low temperature to remove the solvent. At this time, a uniform composite phospholipid film will be formed on the bottom surface of the evaporation container. S2. Mix the phosphate buffer solution, ergothioneine and nicotinamide mononucleotide to obtain an aqueous mixed solution. S3. Add the aqueous mixed solution obtained in S2 to the evaporation container in S1 to hydrate the composite phospholipid membrane at a hydration temperature of about 50°C for about 20 minutes. Then, perform ultrasonic treatment for about 4 minutes at a power of 300W to obtain the prickly pear oil-ergothioneine-NMN composite liposome, which is the above-mentioned active ingredient.

[0060] The preparation methods for the active ingredients in Comparative Examples 1-10 are as follows. The preparation methods for each group are the same as those in Examples 1-3, with adjustments only made to the raw material composition, while maintaining consistent process parameters: Comparative Example 1: S1. Weigh out phospholipids, cholesterol, and sea buckthorn oil and dissolve them fully in ethanol. Stir until completely dissolved and then transfer to an evaporation container. Evaporate at low temperature to remove the solvent and form a composite phospholipid film. S2. Stir and mix the phosphate buffer solution and ergothioneine to obtain an aqueous mixed solution (without adding NMN). S3. Add the aqueous mixed solution obtained in S2 to the evaporation container in S1 to hydrate the composite phospholipid membrane. The hydration temperature is about 50℃ and the hydration time is about 20 minutes. Then, perform ultrasonic treatment for about 4 minutes and the ultrasonic power is 300W to obtain liposomes.

[0061] Comparative Example 2: S1. Weigh out phospholipids, cholesterol, and sea buckthorn oil and dissolve them fully in ethanol. Stir until completely dissolved and then transfer to an evaporation container. Evaporate at low temperature to remove the solvent and form a composite phospholipid film. S2. Stir and mix the phosphate buffer solution and NMN to obtain an aqueous mixed solution; S3, same as step 1 in comparative example.

[0062] Comparative Example 3: S1. Weigh out phospholipids and cholesterol and dissolve them fully in ethanol. Stir until completely dissolved and then transfer to an evaporation container. Evaporate at low temperature to remove the solvent and form a phospholipid film. S2. Stir and mix the phosphate buffer solution, ergothioneine, and NMN to obtain an aqueous mixed solution; S3, same as step 1 in comparative example.

[0063] Comparative Example 4 (containing only sea buckthorn fruit oil): S1. Weigh out phospholipids, cholesterol, and sea buckthorn oil and dissolve them fully in ethanol. Stir until completely dissolved and then transfer to an evaporation container. Evaporate at low temperature to remove the solvent and form a composite phospholipid film. S2. Using only phosphate buffer solution, without adding any active ingredients, stir to obtain an aqueous solution; S3, same as step 1 in comparative example.

[0064] Comparative Example 5: S1. Weigh out phospholipids and cholesterol and dissolve them fully in ethanol. Stir until completely dissolved and then transfer to an evaporation container. Evaporate at low temperature to remove the solvent and form a phospholipid film. S2. Stir and mix the phosphate buffer solution and ergothioneine to obtain an aqueous mixed solution; S3, same as step 1 in comparative example.

[0065] Comparative Example 6: S1. Weigh out phospholipids and cholesterol and dissolve them fully in ethanol. Stir until completely dissolved and then transfer to an evaporation container. Evaporate at low temperature to remove the solvent and form a phospholipid film. S2. Stir and mix the phosphate buffer solution and NMN to obtain an aqueous mixed solution; S3, same as step 1 in comparative example.

[0066] Comparative Example 7: S1. Weigh out phospholipids and cholesterol and dissolve them fully in ethanol. Stir until completely dissolved and then transfer to an evaporation container. Evaporate at low temperature to remove the solvent and form a phospholipid film. S2. Using only phosphate buffer solution, without adding any active ingredients, stir to obtain an aqueous solution; S3, same as step 1 in comparative example.

[0067] Comparative Example 8: S1. Weigh out phospholipids, cholesterol, and jojoba oil and dissolve them fully in ethanol. Stir until completely dissolved and then transfer to an evaporation container. Evaporate at low temperature to remove the solvent and form a composite phospholipid film. S2. Stir and mix the phosphate buffer solution, ergothioneine, and NMN to obtain an aqueous mixed solution; S3, same as step 1 in comparative example.

[0068] Comparative Example 9: S1. Weigh out phospholipids, cholesterol, and sea buckthorn oil and dissolve them fully in ethanol. Stir until completely dissolved and then transfer to an evaporation container. Evaporate at low temperature to remove the solvent and form a composite phospholipid film. S2. Stir and mix the phosphate buffer solution, glutathione, and NMN to obtain an aqueous mixed solution; S3, same as step 1 in comparative example.

[0069] Comparative Example 10: S1. Weigh out phospholipids, cholesterol, and sea buckthorn oil and dissolve them fully in ethanol. Stir until completely dissolved and then transfer to an evaporation container. Evaporate at low temperature to remove the solvent and form a composite phospholipid film. S2. Stir and mix the phosphate buffer solution, ergothioneine, and nicotinamide to obtain an aqueous mixed solution; S3, same as step 1 in comparative example.

[0070] The formula for the face cream based on the above-mentioned active ingredients is shown in Table 4 below.

[0071] Table 4. Proportions of each component in the face cream formula Face cream is prepared using the following method: a. Aqueous phase: Place water in a container equipped with a stirring device and stir. After fully wetting and mixing the other components of phase A, add them to the water and stir thoroughly until completely dissolved. Heat to about 80°C. b. Oil phase; Mix the components of phase B and heat to about 77°C, stirring until completely dissolved; c. Emulsification: Add the oil phase obtained in step b to the aqueous phase obtained in step a, stir at 250-350 rpm for 4 min, and then homogenize at 2500-3500 rpm for 7 min; d. Add each component to phase C, stir at 250-350 rpm for 4 min, then homogenize at 2500-3500 rpm for 7 min, and stir while cooling to 45℃; e. Add each component in phase D, stir at 250-350 rpm for 4 minutes, and then homogenize at 2500-3500 rpm for 7 minutes; f. After cooling to 36℃, add phase E, stir at 250-350 rpm for 7 minutes, then homogenize at 2500-3500 rpm for 7 minutes to obtain the desired face cream.

[0072] Based on the aforementioned active ingredients and face cream, the following experimental groups 1 to 5 and control groups 1 to 7 are further provided. The difference between experimental group 1 and experimental group 2 is only an increase in the content of active liposomes, and the difference between experimental group 3 and experimental group 2 is only a decrease in the content of active liposomes. Experimental groups 1 to 3 compare the changes brought about by changes in the content of active liposomes when the total content of active ingredients contained in the active liposomes is the same. Experimental groups 1, 4, and 5 show the changes brought about by changes in the total content of active ingredients contained in the active liposomes but with unchanged active liposome content. Control groups 1 to 3 compare the changes brought about by active liposomes containing only two active ingredients. Control groups 4 to 6 compare the changes brought about by active liposomes containing only one active ingredient. Control group 7 contains only liposomes and no active ingredients. Control groups 8 to 10 use liposomes prepared by comparative examples 8 to 10, respectively replacing sea buckthorn oil with jojoba oil, ergothioneine with glutathione, and NMN with ordinary niacinamide, with an addition amount of 8%, to compare the synergistic advantages of the three key ingredients selected in this invention.

[0073] Table 5. Raw material distribution ratios for experimental groups 1-5 and control groups 1-7 The examples and comparative examples in the table above refer to the effective ingredients prepared according to their respective formulations.

[0074] II. Efficacy Evaluation Tests of the Experimental Group and the Control Sample In vitro cell experiments (1) Detection of core indicators of mitochondrial function Experimental materials: Cell: Human immortalized keratinocytes (HaCaT).

[0075] Samples: Blank control samples (without active ingredients) in Table 6, test samples 1-5 (complex liposomes with different concentrations / component combinations), control samples 1-7 (single / dual component or ineffective liposomes), and comparative samples 8-10 (liposomes with component replacement).

[0076] Reagents: JC-1 mitochondrial membrane potential detection kit, ATP detection kit (luciferase method), MitoSOX Red mitochondrial superoxide anion probe.

[0077] Experimental steps: 1. Cell seeding and sample processing HaCaT cells were seeded into 24-well plates and cultured until confluence reached 60%-70%. Then, the medium was replaced with serum-free medium containing different samples and cultured for another 24 hours.

[0078] 2. Mitochondrial membrane potential detection After incubating the MitoSOX Red probe, the fluorescence intensity was observed using a fluorescence microscope. The lower the intensity, the lower the ROS level.

[0079] 3. Measurement of ATP production After cell lysis, the supernatant was reacted with ATP detection working solution, and the chemiluminescence intensity was detected by an ELISA reader to calculate the ATP concentration.

[0080] 4. Mitochondrial ROS level detection After incubating the MitoSOX Red probe, the fluorescence intensity was observed using a fluorescence microscope. The lower the intensity, the lower the ROS level.

[0081] Table 6. Proportioning of raw materials for cell experiments Table 7 Experimental values ​​for core indicators of mitochondrial function As shown in Table 7, the prickly pear oil-ergothioneine-NMN complex liposome of the present invention exhibits good mitochondrial function improvement effects in multi-component synergistic, concentration gradient and component deficiency comparison experiments.

[0082] Mitochondrial membrane potential stability: The JC-1 red-green ratio of the blank control sample was only 1.0±0.1, and that of control sample 7 was 1.1±0.1, showing no significant difference from the blank group, indicating that the liposome carrier itself has no additional effect on membrane potential. The JC-1 red-green ratio of test sample 5 was 1.8±0.1, significantly higher than that of all two-component control groups (control samples 1-3) (1.5±0.1~1.5±0.2) and the single-component control group (control samples 4-6) (1.3±0.1), indicating that even with the lowest content of the active ingredient in this invention, its three-component synergistic effect in stabilizing membrane potential is significantly better than the formulation lacking any core component. Furthermore, compared with control samples 8-10, the membrane potential ratio of control samples 8-10 was 1.4±0.1, and the membrane potential stability of test sample 5 was significantly better. This indicates that the specific combination of sea buckthorn oil, ergothioneine and NMN has an irreplaceable synergistic effect in stabilizing mitochondrial membrane potential. Using jojoba oil to replace sea buckthorn oil (control sample 8), glutathione to replace ergothioneine (control sample 9) or ordinary nicotinamide to replace NMN (control sample 10) could not achieve the same effect.

[0083] ATP production capacity: The ATP production of the blank control sample was 5.2±0.3 nmol / well, and that of control sample 7 (empty liposomes) was 5.3±0.2 nmol / well, which was close to that of the blank group. The ATP production of experimental sample 5 was 9.2±0.4 nmol / well, which was significantly better than that of the two-component control group (7.5±0.4~7.6±0.4 nmol / well) and the single-component control group (6.0±0.2~6.1±0.3 nmol / well). Furthermore, the ATP production of controls 8-10 was 6.4±0.2, 6.5±0.3, and 6.3±0.2 nmol / well, respectively, all significantly lower than that of experimental sample 5. This indicates that the alternative components jojoba oil, glutathione, and nicotinamide have limited effects in promoting energy metabolism, further confirming that the synergistic effect of the "thorn fruit oil-ergothioneine-NMN" combination in promoting cellular energy metabolism is indispensable.

[0084] Mitochondrial ROS inhibition effect: The relative value of ROS fluorescence intensity of the blank control sample was 100.0±5.1%, and that of control sample 7 (empty liposomes) was 96.2±6.8%, with no significant difference from the blank group; the mitochondrial ROS level of test sample 5 was 39.4±2.8%, significantly lower than that of the two-component control group (55.3±3.2%~56.7±3.9%) and the single-component control group (76.4±5.1%~79.3±5.0%); the ROS levels of controls 8-10 were 70.1±4.2%, 69.8±4.0%, and 70.2±4.1%, respectively, all much higher than that of test sample 5. This further confirms that the mitochondrial targeted clearance ability of ergothioneine, the multi-pathway antioxidant effect of prickly pear fruit oil, and the energy support of NMN are all indispensable, highlighting the significant synergistic effect of the three components in clearing ROS and reducing oxidative stress. The effect is far superior to that of single or two-component components, and alternative components cannot achieve the same ROS inhibition effect.

[0085] The comparative results of samples 1, 2, and 3 showed that the mitochondrial membrane potential ratio increased with increasing concentration; ATP production and ROS inhibition also showed a concentration gradient. This indicates that within a certain range, the higher the content of the complex liposomes, the more significant its effect on improving mitochondrial function, reflecting a dose-response relationship.

[0086] The comparative results of test samples 1, 4, and 5 showed that even with the same amount of active liposomes added, the improvement effect weakened as the overall content of the active ingredients decreased. More importantly, even test sample 5, with the lowest content of active ingredients, still showed significantly better performance than all dual-component and single-component control groups, fully demonstrating that the combination of "Prickly pear oil-ergothioneine-NMN" produced a synergistic effect of "1+1+1>3," which is key to the significant anti-aging effect achieved by this invention.

[0087] (2) Verification of NAD+ levels and downstream pathway regulation Experimental materials: Cells: Same as HaCaT cells in Experiment 1.

[0088] Samples: Same as the blank control sample, test sample, and control sample in Experiment 1.

[0089] Reagents: NAD+ detection kit, SIRT1 / SIRT3 primary antibody, HRP-labeled secondary antibody, RIPA lysis buffer.

[0090] Experimental steps: 1. Cell seeding and sample processing Same as Experiment 1 (24-well plate, after 24 hours of incubation, replace with serum-free medium containing the sample, and incubate for 24 hours).

[0091] 2. Measurement of intracellular NAD+ levels After cell lysis, the supernatant was collected and incubated with the reaction solution of the NAD+ detection kit. The absorbance at OD450nm was measured using a microplate reader, and the NAD+ concentration was calculated.

[0092] 3. SIRT1 / SIRT3 protein expression detection Total protein was extracted after cell lysis, and subjected to SDS-PAGE electrophoresis, membrane transfer, and antibody incubation (primary antibody: SIRT1, SIRT3, GAPDH; secondary antibody: HRP labeling). After ECL staining, the gray values ​​of the bands were analyzed, and the relative expression level of the target protein was calculated (with GAPDH as an internal control).

[0093] Table 8. Experimental values ​​for NAD+ levels and downstream pathway regulation. As shown in Table 8, the experimental data on NAD+ level and downstream pathway regulation of the present invention demonstrate that the prickly pear oil-ergothioneine-NMN complex liposome significantly increases intracellular NAD+ level and activates its downstream SIRT1 / SIRT3 pathway through the synergistic effect of multiple components.

[0094] Specifically, even in sample 5, which had the lowest content of the active ingredient in this invention, the NAD+ content was 260±11 pmol / well, significantly higher than the 236~239 pmol / well of all dual-component control groups (comparative samples 1-3) and the 213~214 pmol / well of the single-component control groups (comparative samples 4-6). Furthermore, compared to comparative samples 8-10, whose NAD+ contents were 218±6, 219±6, and 218±5 pmol / well respectively, sample 5 still showed a significant advantage in NAD+ level. This indicates that the synergistic effect of the three components in increasing NAD+ level is not only superior to formulations lacking the ingredient, but also significantly superior to formulations using alternative ingredients such as jojoba oil, glutathione, or common nicotinamide.

[0095] Regarding SIRT1 protein expression, the relative expression level of experimental sample 5 was 1.21±0.06, which was significantly higher than that of the two-component control group (1.12-1.13) and the single-component control group (1.04-1.05). The SIRT1 expression levels of control samples 8-10 were 1.09±0.02, 1.09±0.02, and 1.08±0.02, respectively, all lower than that of experimental sample 5. This indicates that the three-component combination has a synergistic enhancing effect on activating the SIRT1 pathway, and this effect cannot be equivalently achieved by the selected alternative components.

[0096] Regarding SIRT3 protein expression, the relative expression level of SIRT3 in experimental sample 5 was 2.49±0.13, which was significantly higher than that in the two-component control group (2.09~2.12) and the single-component control group (1.23~1.24), and more than 1.5 times that in the component replacement group (control samples 8-10) (1.55~1.61). This indicates that the three components of "Stachys aegypti fruit oil-ergothionein-NMN" exhibit a synergistic effect in activating SIRT3, a key regulator of mitochondrial function.

[0097] The comparative results of experimental samples 1, 2, and 3 showed that, under the condition of a fixed total content of active ingredients, the NAD+ level, SIRT1 and SIRT3 protein expression showed a certain gradient change with the increase of active liposome content. This indicates that within the liposome content range of 5%-10%, the regulatory effect of the complex on the NAD+-SIRT pathway increases with the increase of content.

[0098] The comparative results of experimental samples 1, 4, and 5 showed that when the amount of effective liposomes added was fixed (8%), the improvement effect weakened as the overall content of the effective ingredients decreased. More importantly, even in experimental sample 5, which had the lowest content of effective ingredients, the NAD+ level, SIRT1 expression, and SIRT3 expression were still significantly higher than all dual-component control groups, single-component control groups, and component replacement control groups, fully demonstrating that the synergistic effect of the combination of "Stachys aegypti fruit oil-ergothioneine-NMN" is the core mechanism for achieving pathway regulation.

[0099] II. Human Efficacy Testing Characterization data and effect data of the products in the examples and comparative examples (1) Test samples: face creams of test groups 1-5 and control groups 1-10 as described in Table 5.

[0100] (2) Test subjects: 45 healthy female subjects aged 30-60 years were recruited (3 people in each group). The inclusion criteria included: forehead wrinkles grade 3-6, nasolabial folds grade 1-3, crow's feet wrinkles grade 2-4; mean F4 score of cheeks >6 or mean R2 score ≤0.65; positive lactic acid stinging test (total score ≥3 points). Each group used the same formula product. Written informed consent was signed. Before enrollment, a series of questions about medical history and health status were asked to the subjects according to the inclusion and exclusion criteria. At the same time, the skin of the test site was assessed for conformity and skin color was screened, and the results were recorded. Environmental conditions: Visual assessment and instrument testing were conducted in an environment with a temperature of 21±1℃ and a relative humidity of 50±10% RH. Visual assessment was conducted under constant lighting conditions (fluorescent tubes or LED lights with a color temperature of 5500~6500K). Subjects were required to adapt to these environmental conditions for at least 30 minutes before assessment and testing could be performed.

[0101] (3) Test method: Apply the sample twice a day, morning and evening. Apply an appropriate amount of the test sample to the face. Apply sunscreen to the entire face every morning.

[0102] Results were tested at the following three time periods: before sample use (D0), 2 weeks after sample use (W2), and 4 weeks after sample use (W4).

[0103] (4) Evaluation indicators: 1) Corneal moisture content (Corneometer CM 825): the higher the value, the better the moisturizing effect; 2) Transepidermal water loss rate (Tewameter™ Hex): the lower the value, the stronger the barrier function; 3) Skin elasticity (Cutometer MPA 580, R2 value): The higher the R2 value, the better the elasticity. 4) Wrinkle parameters (EvaFACE fast optical imaging system, Antera 3D imaging camera system): The number of forehead wrinkles was collected using the EvaFACE fast optical imaging system, and the texture map under the eyes was captured by the Antera 3D imaging camera system.

[0104] Table 9. Change Rate of Human Efficacy Test Indicators Figure 1 To obtain images of the under-eye skin texture before and after using the face cream of this invention, the Antera 3D imaging camera system was used. This instrument is a common imaging device in the field of cosmetic skin efficacy evaluation. Based on fast optical coherence tomography technology, it can capture parameters such as skin surface texture, wrinkle depth and density at high resolution.

[0105] Table 9 shows the rate of change after 4 weeks of sample use compared to before sample use. Figure 1 (a) shows the under-eye texture before using the sample, (b) shows the under-eye texture after using the sample for 2 weeks, and (c) shows the under-eye texture after using the sample for 4 weeks.

[0106] From Table 9 and Figure 1 It is evident that the prickly pear oil-ergothioneine-NMN complex liposome of the present invention, through the synergistic effect of the three components, can significantly improve skin moisturizing ability, barrier function, elasticity, and wrinkle condition, and the effect gradually increases with the extension of use time. Even in the 8% efficacy liposome test group 5 of Example 3, which has the lowest active ingredient content, its various indicators are still significantly better than the dual-component control group, the single-component control group, the component replacement control group, and the empty liposome control group, fully demonstrating the synergistic effect of "1+1+1>3".

[0107] Specifically, after 4 weeks of use, the stratum corneum moisture content of experimental group 5 increased by 27.6%, significantly higher than the 19.5%~20.7% of the dual-component control group (1-3), the 12.4%~13.1% of the single-component control group (4-6), the 15.7%~16.2% of the component replacement control group (8-10), and the 7.1% of the empty liposome control group (7). The effect was superior to any combination of two components or a single component, significantly improving skin moisturizing ability. The transepidermal water loss rate decreased by 17.5%, which was 4.7%~5.2%, 9.4%~9.7%, and 6.7%~7.3% higher than the 12.3%~12.8% of control group 1-3, the 7.8%~8.1% of control group 4-6, and the 10.2%~10.8% of control group 8-10, respectively. This verifies that the three-component combination can synergistically strengthen the skin barrier integrity and reduce transepidermal water loss. The skin elasticity R2 value increased by 11.7%, significantly higher than that of control groups 1-3 (6.7%-7.2%), control groups 4-6 (3.5%-3.8%), and control groups 8-10 (5.4%-5.8%), indicating that it can promote the reconstruction of the dermal collagen network and enhance skin elasticity. The number of forehead wrinkles decreased by 9.8%, which is 3.2%-3.6%, 6.6%-6.9%, and 4.4%-4.7% higher than that of control groups 1-3 (6.2%-6.6%), control groups 4-6 (2.9%-3.2%), and control groups 8-10 (5.1%-5.4%), respectively, significantly improving the condition of skin wrinkles.

[0108] Figure 1 The above effects were further visually verified using Antera 3D imaging. Figure 1 a shows that the skin texture under the eyes is dense and deep before use; Figure 1 b shows the amount of texture after 2 weeks of use, and the depth has become lighter; Figure 1 c shows that after 4 weeks of use, the texture became sparser and the depth decreased further, which is consistent with the time-dependent change trend of the quantitative indicators in Table 7, confirming that the synergistic effect of the three components gradually accumulates with the extension of the use time, and the anti-aging effect continues to be enhanced.

[0109] The above description of the embodiments is provided to enable those skilled in the art to understand and use the invention. It will be apparent to those skilled in the art that various modifications can be made to these embodiments, and the general principles described herein can be applied to other embodiments without inventive effort. Therefore, the present invention is not limited to the above embodiments, and any improvements and modifications made by those skilled in the art based on the disclosure of the present invention without departing from the scope of the invention should be within the protection scope of the present invention.

Claims

1. A natural plant active ingredient based on cell function regulation, characterized in that, The raw material components include the following parts by weight: 200-400 parts of sea buckthorn fruit oil, 100-300 parts of ergothioneine, and 200-500 parts of nicotinamide mononucleotide.

2. A natural plant composition based on cell function regulation, characterized in that, The raw material components include the following parts by weight: 1000-1600 parts phospholipids, 200-400 parts cholesterol, 200-400 parts sea buckthorn oil, 100-300 parts ergothioneine, and 200-500 parts nicotinamide mononucleotide.

3. The method for preparing a natural plant composition based on cell function regulation as described in claim 2, characterized in that, Includes the following steps: S1. Weigh out phospholipids, cholesterol, and sea buckthorn oil, dissolve them fully in the solvent, stir until completely dissolved, transfer to an evaporation container, remove the solvent, and form a uniform composite phospholipid film on the bottom surface of the evaporation container. S2. Mix the phosphate buffer solution, ergothioneine and nicotinamide mononucleotide to obtain an aqueous mixed solution. S3. Add the aqueous mixed solution obtained in S2 to the evaporation container in S1 to hydrate the composite phospholipid membrane, and then perform ultrasonic treatment to obtain the prickly pear oil-ergothioneine-NMN composite liposome, which is the natural plant composition.

4. The method for preparing a natural plant composition based on cell function regulation according to claim 3, characterized in that, In S1, the mass ratio of cholesterol to phospholipids is (1~2):(5~8); the mass ratio of sea buckthorn fruit oil to phospholipids is (1~2):(5~8). The solvent used is ethanol.

5. The method for preparing a natural plant composition based on cell function regulation according to claim 3, characterized in that, In S2, the ratio of phosphate buffer solution, ergothioneine and nicotinamide mononucleotide added is (20~40) mL: (100~300) mg: (200~500) mg; The pH of the phosphate buffer solution is 6.5~7.

0.

6. The method for preparing a natural plant composition based on cell function regulation according to claim 3, characterized in that, In S3, the addition amounts of the aqueous mixed solution and the composite phospholipid membrane satisfy the following mass ratio: ergothionein to nicotinamide mononucleotide (200~400): (100~300): (200~500). In S3, the hydration treatment temperature is 45~55℃ and the time is 15~30 minutes; The ultrasonic treatment time is 3 to 5 minutes, and the ultrasonic power is 200 to 400 W.

7. The application of the natural plant composition based on cell function regulation as described in claim 2 in the preparation of anti-skin aging skin care products.

8. The application of the natural plant composition based on cell function regulation according to claim 7, characterized in that, The anti-aging skincare products mentioned are face creams, toners, serums, or lotions.

9. An anti-aging skincare product, characterized in that, It includes a matrix excipient and an active ingredient, wherein the active ingredient is a natural plant active ingredient as described in claim 1 or a natural plant composition as described in claim 2, wherein the amount of the active ingredient added is 5-10 wt%.

10. The anti-aging skincare product according to claim 9, characterized in that, This skincare product is a face cream. The base excipients include phase A, phase B, phase C, and phase D excipients. The total weight of the skincare product is calculated as follows: The A-phase excipients include 5-10% glycerol, 3-10% propylene glycol, 0.5-2% trehalose, 0.01-1% sodium hyaluronate, 0.5-5% nicotinamide, 0.1-5% panthenol, 0.1-2% acrylate / C10-30 alkanol acrylate crosspolymer, 0.1-2% PEG-100 stearate, and 0.01-1% disodium EDTA. Phase B excipients include isopropyl isostearate 0.1-5%, caprylic / capric triglyceride 0.1-5%, glyceryl stearate 0.1-5%, polydimethylsiloxane 0.1-4%, squalane 0.1-5%, cetearyl alcohol 0.1-5%, behenol 0.1-2%, and polysorbate-80 0.1-2%; Phase C excipients include 0.1-2% arginine; Phase D excipients include 0.1-2% fragrance and 0.01-1% phenoxyethanol.

Images